Montelukast sodium NEW

Get Latest Price

Min. Order1kg
Purity99%
Cas No151767-02-1
Supply Ability20tons
Update time2024-04-18

Shaanxi TNJONE Pharmaceutical Co., Ltd

1YR

China

Chemical Properties

Product Name	Montelukast sodium
CAS No	151767-02-1
EC-No	604-813-7
Min. Order	1kg
Purity	99%
Supply Ability	20tons
Release date	2024/04/18

Items	Standard	Results
APPEARANCE	Off white to white powder	White powder
IDENTIFICATION	A: IR B: Retention time	Complies Complies
WATER	≤0.5%	0.06%
HEAVY METALS	≤0.002%	Complies
ISOMERS	SFBD1≤0.15%	Undetected
	SFBD2≤0.15%	Undetected
	SFBE≤0.15%	Undetected
RELATED SUBSTANCES	SFBA-1≤0.15%	0.04%
	SFBMA≤0.15%	Undetected
	CHLORO-SFB≤0.15%	0.05%
	DiSFBMA-SFB≤0.15%	0.02%
	Methyl-SFB≤0.15%	Undetected
	Pentafluoro-phenol≤0.15%	Undetected
	Amino-SFB≤0.15%	Undetected
	Any unknown impurity≤0.1%	0.04%
	Total impurity≤1.0%	0.21%
RESIDUE SOLBENTS	Methanol≤3000ppm	Undetected
	Isopropyl alcohol≤5000ppm	19ppm
	Dichloromethane≤600ppm	Undetected
	Tetrahydrofuran≤720ppm	Undetected
	Acetic acid≤5000ppm	Undetected
	Toluene≤890ppm	Undetected
	Chlorobenzene≤360ppm	Undetected
	Methyl tert-butyl ether≤5000ppm	103ppm
ASSAY	≥99.0%	99.8%

Product Name: Montelukast sodium
Synonyms: singulair;MONTELUKAST NA;MONTELUKAST SODIUM;mk-476;2-[1-[[1-[3-[2-[(7-chloro-2-quinolyl)]vinyl]phenyl]-3-[2-(1-hydroxy-1-methyl-ethyl)phenyl]-propyl]sulfanylmethyl]cyclopropyl]acetic acid sodium salt;1-[1-[[[(1R)-1-[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic;MK-476, Singulair;Montelukast, Sodium Salt
CAS: 151767-02-1
MF: C35H35ClNNaO3S
MW: 608.17
EINECS: 604-813-7
Melting point: 115 °C(dec.)
Storage temp.: -20°C Freezer, Under Inert Atmosphere

Description:

Montelukast was launched as Singulair in Mexico and Finland for the management of mild to moderate asthma inadequately controlled by inhaled corticosteroids and short-acting beta2-agonists. Montelukast can be obtained by an seven-step synthesis from 3-[2(E)-(7-chloroquinolin-2-yl)vinyl] benzaldehyde. Montelukast is a potent, selective and orally active antagonist of the CysLT1 (formerly called LTD4) receptor, thus blocking the effects of the cysteinyl leukotrienes LTC4, LTD4 and LTE4 on microvascular permeability and the activation of eosinophils.

Montelukast represents the third molecule of this class which has been approved in asthma after pranlukast (1995) and zafirlukast (1996). Montelukast has been studied extensively in placebo-controlled clinical trials, in mildly or severe asthmatic patients challenged with LTD4 or exercise. A variety of acute bronchoconstricting challenges were inhibited or attenuated with all doses used.

Montelukast demonstrated clinically significant improvements in the parameters of asthma control associated with an appreciable improvement in quality of life., reducing days with asthma exacerbations and allowing significant tapering of corticosteroids. Montelukast is well-tolerated and only needs to be administered once a day.